

# Presentation of proposed board members

The Nomination Committee's proposal AGM 2018 (item 11 in the proposed agenda)



**New election of:**

**Denise Goode**

*Born:* 1958

*Education:* Institute of Chartered Accountants in England and Wales Chartered Accountant. B.Sc. Zoology from The University of Manchester (UK)

*Other ongoing assignments:* Director of QED Life Sciences Limited. Director of AnaMar AB.

*No. of shares in NeuroVive:* -

*Other:* Non-affiliated to the company, the management, and to major owners.

Denise Goode, Chartered Accountant, established QED Life Sciences Limited in 2014, a consultancy business through which she currently advises and supports the strategic direction of a number of biotech clients. Denise has extensive financial, commercial and industry deal making experience, including 20 years with AstraZeneca having served in senior finance & business roles, latterly as Executive Business Development Director in the AstraZeneca Global Portfolio and Product Strategy team where she led the execution of transformational global deals. She is a highly experienced dealmaker with an extensive track record and a deep understanding of disease landscapes, therapeutic intervention strategies, and regulatory and competitor environments. Since 2015 as VP Business Development of AnaMar AB she has worked collegiately with the Board, the CEO and a team of scientists. During 2017 Denise was appointed to the Board of AnaMar.



**Re-election of:**

**David Laskow-Pooley**

*Chairman (2017)*

*Born:* 1954

*Education:* BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP., Sunderland School of Pharmacy.

*Other assignments:* Director of the board of TapImmune Inc, USA, LREsystem Ltd, England and Pharmafor Ltd, England.

*Previous assignments the past five years:* Chairman of OBN Ltd (United Kingdom) and Director of the board of Venturefest Oxford Ltd (United Kingdom).

*No. of shares in NeuroVive:* -

*Other:* Non-affiliated to the Company, the management and to major owners.



**Re-election of:**

**David Bejker**

*Director (2013)*

*Born:* 1975

*Education:* M.Sc. (Econ.), Stockholm School of Economics.

*Other assignments:* CEO of Affibody Medical AB

*Previous assignments the past five years:* Deputy director of the board of Nexstim OY.

*No. of shares in NeuroVive:* -

*Other:* Non-affiliated to the Company, the management and to major owners.



**Re-election of:**

**Marcus Keep**

*Director (2000)*

*Born:* 1959

*Education:* BSc in Chemistry from University of South Carolina. BA in Religion from Dartmouth College. MD from Medical University of South Carolina. Neurosurgery specialty training from Montreal Neurological Institute, McGill University.

*Other assignments:* CEO and chair of Maas Biolab LLC (USA) and CEO of Keep Enterprises, LLC (USA) and Restorative Neurosurgery Foundation (USA). Concluded assignments 2016:

*Previous assignments the past five years:* Associate Professor of Neurosurgery, Penn State Hershey Medical Center, Pennsylvania (USA), Chief of Neurosurgery at Penn State Health-St. Joseph Medical Center.

*No. of shares in NeuroVive:* 425 929 shares (including family) and shares in Maas Biolab LLC (owner of 3 874 432 shares in NeuroVive) where Marcus Keep controls 48.44 percent of the shares.

*Other:* Non-affiliated to the Company, the management and to major owners.



**Re-election of:**

**Jan Törnell**

*Director (2016)*

*Born:* 1960

*Education:* MD and PhD in physiology, University of Gothenburg.

*Other assignments:* Adjunct Professor at the Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg. Jan is also chairman of the Board at LIDDS AB, Glactone Pharma AB and Glactone Pharma Development AB and Director of the Board at Stayble AB and Diaprost AB, CEO at Innoext AB and partner of P.U.L.S. AB.

*Previous assignments the past five years:* -

*No. of shares in NeuroVive:* -

*Other:* Non-affiliated to the Company, the management and to major owners.